IMCR Stock Summary and Trading Ideas (Immunocore Hldgs | NASDAQ:IMCR)

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.

Immunocore Hldgs trades on the NASDAQ stock market under the symbol IMCR.

As of January 31, 2025, IMCR stock price climbed to $32.88 with 155,402 million shares trading.

IMCR has a beta of 1.11, meaning it tends to be more sensitive to market movements. IMCR has a correlation of 0.10 to the broad based SPY ETF.

IMCR has a market cap of $1.64 billion. This is considered a Small Cap stock.

Last quarter Immunocore Hldgs reported $80 million in Revenue and $.17 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.51.

In the last 3 years, IMCR traded as high as $76.98 and as low as $21.00.

The top ETF exchange traded funds that IMCR belongs to (by Net Assets): IBB, SPDW, SBIO, GWX, ONEQ.

IMCR has underperformed the market in the last year with a return of -51.4%, while the SPY ETF gained +24.0%. In the last 3 month period, IMCR fell short of the market, returning +3.0%, while SPY returned +4.1%. However, in the most recent 2 weeks IMCR has outperformed the stock market by returning +13.0%, while SPY returned +1.7%.

IMCR support price is $31.51 and resistance is $33.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMCR shares will trade within this expected range on the day.